These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11167799)

  • 1. The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.
    Paterson PJ; McWhinney PH; Potter M; Kibbler CC; Prentice HG
    Br J Haematol; 2001 Jan; 112(1):175-80. PubMed ID: 11167799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients.
    Wong-Beringera A; Hindler J; Brankovic L; Muehlbauer L; Steele-Moore L
    Diagn Microbiol Infect Dis; 2001 Jan; 39(1):25-31. PubMed ID: 11173188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
    Tumbarello M; Caldarola G; Tacconelli E; Morace G; Posteraro B; Cauda R; Ortona L
    J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution.
    Lass-Flörl C; Gunsilius E; Gastl G; Englisch M; Koch G; Ulmer H; Dierich MP; Petzer A
    Ann Hematol; 2003 Sep; 82(9):565-9. PubMed ID: 14504812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
    Khedri S; Santos ALS; Roudbary M; Hadighi R; Falahati M; Farahyar S; Khoshmirsafa M; Kalantari S
    Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
    Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
    Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice.
    Van t Wout JW; Mattie H; van Furth R
    Antimicrob Agents Chemother; 1989 Feb; 33(2):147-51. PubMed ID: 2541654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Itraconazole in neutropenic patients.
    van't Wout JW
    Chemotherapy; 1992; 38 Suppl 1():23-6. PubMed ID: 1319311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies.
    Myoken Y; Kyo T; Fujihara M; Sugata T; Mikami Y
    Haematologica; 2004 Mar; 89(3):378-80. PubMed ID: 15020289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of azole antifungal agents for systemic antifungal therapy.
    Lee YP; Goldman M
    Cleve Clin J Med; 1997 Feb; 64(2):99-106. PubMed ID: 9046687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of antifungal prophylaxis on the gastrointestinal yeast colonisation in patients with haematological malignancies].
    Rimek D; Redetzke K; Kappe R
    Mycoses; 2006; 49 Suppl 2():18-23. PubMed ID: 17022757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome.
    Krcmery V; Oravcova E; Spanik S; Mrazova-Studena M; Trupl J; Kunova A; Stopkova-Grey K; Kukuckova E; Krupova I; Demitrovicova A; Kralovicova K
    J Antimicrob Chemother; 1998 Mar; 41(3):373-80. PubMed ID: 9578164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prophylaxis against mycoses in neutropenic patients].
    Arning M; Aul C
    Mycoses; 1994; 37 Suppl 2():70-6. PubMed ID: 7541892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer.
    Bodey GP; Mardani M; Hanna HA; Boktour M; Abbas J; Girgawy E; Hachem RY; Kontoyiannis DP; Raad II
    Am J Med; 2002 Apr; 112(5):380-5. PubMed ID: 11904112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
    Martín E; Parras P; Lozano MC
    Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of candidiasis and cryptococcosis in AIDS].
    Just-Nübling G
    Mycoses; 1994; 37 Suppl 2():56-63. PubMed ID: 7609745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
    Krcmery V; Barnes AJ
    J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe candidal infections in neutropenic patients.
    Swerdloff JN; Filler SG; Edwards JE
    Clin Infect Dis; 1993 Nov; 17 Suppl 2():S457-67. PubMed ID: 8274612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral azole drugs as systemic antifungal therapy.
    Como JA; Dismukes WE
    N Engl J Med; 1994 Jan; 330(4):263-72. PubMed ID: 8272088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.